Clinical trialPhase 1Withdrawn
Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
- Outcome
- Stopped earlyWe need to make significant adjustments to proposed drug and its delivery method (Other)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- July 2019
- Planned end
- December 2021
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Feasibility as determined by technical success of Pancreatic Retrograde Venous Infusion (PRVI) with gemcitabine and Lipiodol®; Safety as measured by number of participants with Grade 3, 4, and 5 toxicities
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 27 January 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Catheter directed retrograde venous infusion of gemcitabine/lipiodol into pancreatic tumors.
Detailed description public domain (ClinicalTrials.gov)
Overall, subjects with resectable, borderline-resectable and/or locally-advanced pancreatic cancer are eligible to be entered into the study. Each enrolled study subject will receive a single neoadjuvant pancreatic retrograde venous infusion (PRVI) administration of the gemcitabine/Lipiodol® emulsion. Complete enrollment in 12 months from date of enrollment of first study subject.